Vitroprobe Analytics develops biomolecular analysis techniques using Atom Probe Tomography (APT) to examine drug targets at near-atomic resolution. This technology enables pharmaceutical companies to fine-tune drug candidates more efficiently, reducing the time and cost associated with drug development.
Funding
$50K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of new pharmaceuticals is a slow and expensive process, requiring a detailed understanding of how drug candidates interact with their targets in the body. Current biomolecular analysis techniques lack the resolution needed to examine drug targets at a near-atomic level, hindering the fine-tuning of new pharmaceuticals.
Solution
Vitroprobe Analytics offers biomolecular analysis techniques using Atom Probe Tomography (APT) to examine drug targets at near-atomic resolution. Their patented technique embeds proteins in a silica matrix, preserving the molecules in their native state while enabling high-resolution analysis via APT. This approach allows pharmaceutical companies to gain unique insights into drug-target interactions, facilitating the fine-tuning of drug candidates and accelerating the drug development process. Microgram quantities of the protein of interest are sufficient to produce enough material for analysis and obtain high-quality information.
Target Audience
Vitroprobe's primary customers are pharmaceutical companies and academic researchers involved in drug discovery and development.
Features
- Biomolecular analysis using Atom Probe Tomography (APT)
- Patented technique for embedding proteins in a silica matrix
- Preserves sensitive molecules in their native state during analysis
- Near-atomic resolution imaging of drug-target interactions
- Requires only microgram quantities of protein for analysis